Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 6

NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

Sayfa
505–510
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The rate of PPI use in the patient group of this study was found still quite insufficient.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Using proton-pump inhibitor (PPI) is a protective option for patients who require long-term non-steroidal anti-inflammatory drugs (NSAIDs) and antiaggregants.
📊
Temel Bulgular & Veri:In our previous study, the rate of PPI use in prophylaxis was found to be 2%.
💡
Sonuç & Katkı:The rate of PPI use in the patient group of this study was found still quite insufficient.
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Using proton-pump inhibitor (PPI) is a protective option for patients who require long-term non-steroidal anti-inflammatory drugs (NSAIDs) and antiaggregants. In our previous study, the rate of PPI use in prophylaxis was found to be 2%. Here weaimed to investigate whether there is a change in PPI use in prophylaxis in a similar patient group after 10 years.Materials and Methods: The patients who followed up with upper gastrointestinal (GI) bleeding diagnosis between January 01, 2016 andDecember 31, 2017 were retrospectively evaluated. Patients who had malignancy or variceal hemorrhage were excluded. Ninety-six patients, who had taken NSAIDs, antiaggregants, or anticoagulants that were considered as the possible cause of bleeding, were includedin the study. Risk groups for NSAID GI toxicity and PPI use rates in these patients were evaluated.Results: Twenty (21%) of all patients with upper GI bleeding were using PPI. According to the pre-bleeding risk factor assessment, 86%of the patients were found to have moderate to high risk for NSAID-related GI bleeding, and 81% of these patients were not using PPI.PPI prophylaxis was not provided to 15 (75%) of the 20 patients with previous history of peptic ulcer bleeding.Conclusion: Despite many studies and recommendations on risk factors and prophylaxis for NSAID-related bleeding, prophylactic PPIuse is still largely ignored by physicians. The rate of PPI use in the patient group of this study was found still quite insufficient.

🔖

Bu Makaleye Atıf Yap

DİNÇER, D., KARANCI, E. U., AKIN, M., ADANIR, H. (2019). NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 6, 505–510. https://ajindex.com/articles/408817

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Klein A, Gralnek IM. Acute, nonvariceal upper gastrointestinal bleeding. Curr Opin Crit Care 2015; 21: 154-62. [CrossRef] 2. Hreinsson JP, Kalaitzakis E, Gudmundsson S, Bjornsson ES. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol 2013; 48: 439-47. [CrossRef] 3. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38. [CrossRef] 4. Dincer D, Duman A, Dikici H, Arici C, Suleymanlar I, Isitan F. NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis? Int J Clin Pract 2006; 60: 546-8. [CrossRef] 5. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331: 717-27. [CrossRef] 6. Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2: 394-7. [CrossRef] 7. Retail & Provider Perspective NPA, 1999-2000.
  2. Plymouth, PA: IMS Health. 2000. 8. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606. [CrossRef] 9. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-83. [CrossRef] 10. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801. [CrossRef] 11. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-38. [CrossRef] 12. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325-35. [CrossRef] 13. Brooks J, Warburton R, Beales IL. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis 2013; 4: 206-22. [CrossRef] 14. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis